Ignite Creation Date:
2025-12-18 @ 9:46 AM
Ignite Modification Date:
2025-12-23 @ 6:12 PM
Study NCT ID:
NCT06982313
Status:
None
Last Update Posted:
2025-05-25 00:00:00
First Post:
2025-05-13 00:00:00
Is Possible Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Long-term Follow-up of the TAM-01 Study
Sponsor:
None
Organization:
Study Overview
Official Title:
Long-term Follow-up of the TAM-01 Study, a Phase III Trial of Low Dose Tamoxifen in Breast DCIS and Premalignant Disease
Status:
None
Status Verified Date:
2025-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
TAM-01 L_FU
Brief Summary:
Low-dose tamoxifen (5 mg/day for three years) has emerged as a safer alternative to standard-dose tamoxifen (20 mg/day), effectively reducing the risk of breast cancer recurrence while minimizing adverse events. The TAM-01 phase III trial demonstrated that this regimen decreased subsequent breast cancer events by 42% compared to placebo after 10 years in women with ductal carcinoma in situ (DCIS) or high-risk lesions (atypical ductal hyperplasia, ADH, or lobular carcinoma in situ, LCIS), without exceeding serious adverse events and patient-reported outcomes, thus supporting its wide uptake in the medical community and NCCN guideline inclusion.
The IBIS-I trial reinforced the role of tamoxifen in breast cancer prevention, demonstrating a lasting reduction in breast cancer incidence, particularly in estrogen receptor-positive tumors, with benefits extending beyond the treatment period. Furthermore, real-world evidence indicates strong patient preference for low-dose tamoxifen due to its reduced side effects, increasing adherence in clinical practice. Additionally, studies have shown that low-dose tamoxifen can lower mammographic density, potentially improving screening sensitivity and facilitating earlier cancer detection.
The TAM-01 (EudraCT number: 2007-007740-10) trial was a multicenter, phase III trial comparing 5 mg/day tamoxifen to placebo over 3 years in 500 women aged 75 years or younger with an ECOG performance status of 1 or lower, and hormone-sensitive (ER or progesterone receptor ≥ 1%) or unknown DCIS (69%) or breast intraepithelial neoplasia (ADH, 20% or LCIS, 11%). Women with high-grade or comedo/necrotic DCIS were treated with adjuvant radiotherapy at 50 Gy in 25 fractions. Participants were followed up every 6 months, undergoing annual mammography and transvaginal ultrasound for 3 years of treatment and then being seen annually for 7 years of follow-up. All breast-related events during the trial were centrally adjudicated by an expert committee. The primary endpoint was the incidence of invasive breast cancer and DCIS.
The mean (SD) age at treatment initiation was 54 (9) years, with 58% being postmenopausal women. After a median follow-up of 9.7 years (IQR, 8.3 to 10.9 years), 66 breast cancers were diagnosed (15 in situ; 51 invasive): 25 in the tamoxifen group and 41 in the placebo group (annual rate per 1,000 person-years: 11.3 with tamoxifen vs. 19.5 with placebo; hazard ratio \[HR\] 0.58; 95% CI, 0.35 to 0.95; p = 0.03). The majority of recurrences were invasive (77%) and ipsilateral (59%). For contralateral breast cancer incidence, there were 6 events in the tamoxifen group and 16 in the placebo group (HR, 0.36; 95% CI, 0.14 to 0.92; p = 0.025). No differences were observed between the groups regarding patient-reported outcomes (menopausal symptoms) or serious adverse events during the extended follow-up period.
An exploratory analysis from TAM-01 suggested that the efficacy of low-dose tamoxifen may differ by menopausal status. Although a protective effect was observed in both groups, the reduction appeared more pronounced in postmenopausal women (HR: 0.30; 95% CI, 0.11 to 0.82) than in premenopausal women (HR: 0.73; 95% CI, 0.30 to 1.76). Although this difference did not reach statistical significance (p-interaction = 0.13), it raises important questions about the biological mechanisms underlying tamoxifen's effects and the role of estradiol levels in modulating its efficacy.
The importance of identifying the optimal dose of tamoxifen is underscored by studies demonstrating that lower doses can retain efficacy while significantly reducing adverse effects, supporting the integration of low-dose regimens into prevention strategies. Randomized trials, such as those by Eriksson et al. and Bhatia et al., have shown the potential of low-dose tamoxifen in diverse populations, including high-risk individuals and those with preinvasive breast cancer.
Recent findings from a preplanned biomarker analysis of the TAM-01 trial have provided further support for the role of low-dose tamoxifen in targeted breast cancer prevention strategies. Specifically, baseline levels of insulin-like growth factor binding protein-3 (IGFBP-3) in the top three quartiles (≥3.44 μg/mL), but not in the lowest quartile, were shown to predict greater efficacy of BabyTam compared with placebo (p-interaction = 0.006). In contrast, baseline levels of IGF-I, estradiol, or sex hormone-binding globulin (SHBG) were not predictive of BabyTam efficacy, whereas the IGF-I/IGFBP-3 molar ratio showed a borderline significant interaction (p-interaction = 0.067). This study unveils the potential of serum biomarkers, specifically IGFBP-3 and IGF-I/IGFBP-3 ratios, as predictive factors of BabyTam efficacy among individuals with DCIS or high-risk lesions. These findings hold significant implications in clinical practice, offering a means to discern patients who may derive maximal benefits from BabyTam.
The previous TAM-01 study discontinued the follow-up of enrolled patients because, under Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, the study would have had to be migrated to the Clinical Trials Information System (CTIS) managed by the European Medicines Agency (EMA).
As the study had started in 2008, both the protocol and the entire study documentation were not compliant with the requirements of the Regulation (EU) No 536/2014. For both administrative and feasibility reasons, the migration was not possible, and the original study was therefore closed and replaced by the current version.
Based on the TAM-01 findings, this long-term follow-up study aims to compare the long-term outcomes in women who participated in the TAM-01 trial. By extending the follow-up, the study aims to compare the incidence of invasive breast cancer and DCIS, considering tumor laterality and menopausal status, as well as to assess other non-invasive events (LCIS, ADH or ALH) and adverse outcomes of special interest.
The results of this study are expected to provide a robust evidence base for the incorporation of low-dose tamoxifen into routine clinical practice and to address personalized preventive strategies in high-risk populations.
The IBIS-I trial reinforced the role of tamoxifen in breast cancer prevention, demonstrating a lasting reduction in breast cancer incidence, particularly in estrogen receptor-positive tumors, with benefits extending beyond the treatment period. Furthermore, real-world evidence indicates strong patient preference for low-dose tamoxifen due to its reduced side effects, increasing adherence in clinical practice. Additionally, studies have shown that low-dose tamoxifen can lower mammographic density, potentially improving screening sensitivity and facilitating earlier cancer detection.
The TAM-01 (EudraCT number: 2007-007740-10) trial was a multicenter, phase III trial comparing 5 mg/day tamoxifen to placebo over 3 years in 500 women aged 75 years or younger with an ECOG performance status of 1 or lower, and hormone-sensitive (ER or progesterone receptor ≥ 1%) or unknown DCIS (69%) or breast intraepithelial neoplasia (ADH, 20% or LCIS, 11%). Women with high-grade or comedo/necrotic DCIS were treated with adjuvant radiotherapy at 50 Gy in 25 fractions. Participants were followed up every 6 months, undergoing annual mammography and transvaginal ultrasound for 3 years of treatment and then being seen annually for 7 years of follow-up. All breast-related events during the trial were centrally adjudicated by an expert committee. The primary endpoint was the incidence of invasive breast cancer and DCIS.
The mean (SD) age at treatment initiation was 54 (9) years, with 58% being postmenopausal women. After a median follow-up of 9.7 years (IQR, 8.3 to 10.9 years), 66 breast cancers were diagnosed (15 in situ; 51 invasive): 25 in the tamoxifen group and 41 in the placebo group (annual rate per 1,000 person-years: 11.3 with tamoxifen vs. 19.5 with placebo; hazard ratio \[HR\] 0.58; 95% CI, 0.35 to 0.95; p = 0.03). The majority of recurrences were invasive (77%) and ipsilateral (59%). For contralateral breast cancer incidence, there were 6 events in the tamoxifen group and 16 in the placebo group (HR, 0.36; 95% CI, 0.14 to 0.92; p = 0.025). No differences were observed between the groups regarding patient-reported outcomes (menopausal symptoms) or serious adverse events during the extended follow-up period.
An exploratory analysis from TAM-01 suggested that the efficacy of low-dose tamoxifen may differ by menopausal status. Although a protective effect was observed in both groups, the reduction appeared more pronounced in postmenopausal women (HR: 0.30; 95% CI, 0.11 to 0.82) than in premenopausal women (HR: 0.73; 95% CI, 0.30 to 1.76). Although this difference did not reach statistical significance (p-interaction = 0.13), it raises important questions about the biological mechanisms underlying tamoxifen's effects and the role of estradiol levels in modulating its efficacy.
The importance of identifying the optimal dose of tamoxifen is underscored by studies demonstrating that lower doses can retain efficacy while significantly reducing adverse effects, supporting the integration of low-dose regimens into prevention strategies. Randomized trials, such as those by Eriksson et al. and Bhatia et al., have shown the potential of low-dose tamoxifen in diverse populations, including high-risk individuals and those with preinvasive breast cancer.
Recent findings from a preplanned biomarker analysis of the TAM-01 trial have provided further support for the role of low-dose tamoxifen in targeted breast cancer prevention strategies. Specifically, baseline levels of insulin-like growth factor binding protein-3 (IGFBP-3) in the top three quartiles (≥3.44 μg/mL), but not in the lowest quartile, were shown to predict greater efficacy of BabyTam compared with placebo (p-interaction = 0.006). In contrast, baseline levels of IGF-I, estradiol, or sex hormone-binding globulin (SHBG) were not predictive of BabyTam efficacy, whereas the IGF-I/IGFBP-3 molar ratio showed a borderline significant interaction (p-interaction = 0.067). This study unveils the potential of serum biomarkers, specifically IGFBP-3 and IGF-I/IGFBP-3 ratios, as predictive factors of BabyTam efficacy among individuals with DCIS or high-risk lesions. These findings hold significant implications in clinical practice, offering a means to discern patients who may derive maximal benefits from BabyTam.
The previous TAM-01 study discontinued the follow-up of enrolled patients because, under Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, the study would have had to be migrated to the Clinical Trials Information System (CTIS) managed by the European Medicines Agency (EMA).
As the study had started in 2008, both the protocol and the entire study documentation were not compliant with the requirements of the Regulation (EU) No 536/2014. For both administrative and feasibility reasons, the migration was not possible, and the original study was therefore closed and replaced by the current version.
Based on the TAM-01 findings, this long-term follow-up study aims to compare the long-term outcomes in women who participated in the TAM-01 trial. By extending the follow-up, the study aims to compare the incidence of invasive breast cancer and DCIS, considering tumor laterality and menopausal status, as well as to assess other non-invasive events (LCIS, ADH or ALH) and adverse outcomes of special interest.
The results of this study are expected to provide a robust evidence base for the incorporation of low-dose tamoxifen into routine clinical practice and to address personalized preventive strategies in high-risk populations.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: